Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shuren: FDA Willing to Kick-Start Device Evaluation Program, But Funding Guarantee Needed

This article was originally published in The Gray Sheet

Executive Summary

CDRH Director Jeff Shuren says FDA is willing to foot the bill for a coordinating center to help launch a new "national device evaluation system," but it is contingent on a guarantee that the program would be funded by the upcoming user fee reauthorization.

You may also be interested in...



Digital Health, Cybersecurity Would See Significant Chunk Of FDA Device-Funding Boost

If Congress approves a 26% higher 2019 funding request for US FDA's device center, a substantial chunk of those dollars would go to building a novel framework for regulating digital-health technologies, and to help FDA and device manufacturers respond better to cybersecurity vulnerabilities, among other program priorities, according to agency officials.

JAMA Editorials Call For Tough FDA Sanctions, Device Coding, To Ensure Post-Market Safety

Two Harvard Medical School professors argue US FDA should put pressure on device manufacturers to complete their post-market studies by withdrawing market authority for devices when sponsors do not meet post-approval commitments. Meanwhile, in the same issue of the Journal of the American Medical Association, a Michigan University researcher suggests tracking products with device-specific CPT codes.

$30m In Device User Fees Will Go To Real-World Evidence Evaluation System

US FDA will be able to tap $30m in user fees over a five-year span to support an independent coordinating center for collection of real-world evidence under its nascent NEST program, according to device center Director Jeff Shuren.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel